ABSTRACTS

V. INTERNATIONAL SYMPOSIUM ON HUMAN PURINE AND PYRIMIDINE METABOLISM

San Diego, California U.S.A.

July 28–August 1, 1985

ORGANIZING COMMITTEE

**J. E. Seegmiller, Chairman
G. R. Bartlett
G. R. Boss
T. Friedmann
H. E. Gruber
S. S. Matsumoto
W. L. Nyhan
T. M. Page
L. F. Thompson
R. C. Willis**

THE EFFECT OF PHOSPHONOFORMIC ACID ON WILD TYPE AND
1 MUTANT S49 CELL LINES. D.A. Albert and L.J. Gudas.
Univ. of Chicago and Harvard Medical School.

Phosphonoformic acid (PFA) and its congener phosphonoacetic acid (PAN) are inhibitors of viral (and to a less extent mammalian) DNA polymerase. We selected mutants of S49 cells (a mouse T lymphoma line) resistant to 3mM phosphonoformic acid. These 11 lines had a range of growth rates, cell cycle distribution abnormalities, and concomitant resistance to the inhibitory effects of thymidine, acycloguanosine (acyclovir), aphidicolin, deoxyadenosine, and novobiocin. Most lines had normal to slightly elevated pools of ribonucleoside triphosphates and deoxyribonucleoside triphosphates. However, one line (PFA 3-9) had a greatly elevated dCTP pool and increased CDP reductase activity in permeabilized cells. This activity in the PFA 3-9 cells diminished to wild type control levels in the presence of phosphonoformic acid, while PFA greatly diminished wild type CDP reductase activity (see table). In addition, 4mM PFA diminished the dCTP pool in wild type and in PFA 3-9 cells at 8 hours. The reduced dCTP pool could be increased by exogenous deoxycytidine but this only marginally reversed PFA toxicity. These observations suggest that PFA is an inhibitor of mammalian ribonucleotide reductase and partial resistance to PFA can be effected by mutation to increased CDP reductase activity resulting in a large dCTP pool.

	Growth % Control	CDP Reductase Activity	dCTP	dTTP	dATP	dGTP
Wild Type	100	4855	30.8	46.0	31.9	14.0
+4mM PFA	11.4	1605	14.4	26.6	34.9	12.7
PFA 3-9	100	15040	187.8	59.9	37.5	20.1
+4mM PFA (8hr)	18.9	6110	70.0	26.6	34.9	12.7

2 CHARACTERIZATION OF HYDROXYUREA(HYU) RESISTANT S49 T
LYMPHOMA CELLS. D. Albert and L.J. Gudas. Univ. of
Chicago and Harvard Medical School.

We selected hydroxyurea resistant S49T lymphoma cells by exposing wild type cells to increasing concentrations of hydroxyurea—an inhibitor of ribonucleotide reductase that binds to the M2 subunit of the enzyme. These 10 to 60 fold resistant cell lines demonstrated increased ribonucleotide reductase activity and deoxyribonucleoside triphosphate pools consistent with the hypothesis that the activity of the M2 subunit of ribonucleotide reductase is rate limiting for both ribonucleotide reductase activity and deoxyribonucleoside triphosphate production. Assay of partially purified cell extracts containing M1 or M2 demonstrated the increased M2 activity in HYU resistant cells. Two dimensional gel electrophoresis demonstrated a single spot of increased intensity (pI=5.5 M.W. 50K daltons) in HYU resistant cells which was proportional to the increased M2 activity. In addition hydroxyurea resistant cells were partially resistant to deoxyadenosine toxicity. Cytofluorimetry of HYU resistant cells showed a normal cell cycle distribution which was unchanged after exposure to dibutyryl cyclic AMP in contrast to wild type S49 cells which accumulate in G1 (>90%). Similarly hydroxyurea resistant cells did not arrest in G1 when exposed to Forskolin as wild type S49 cells do. However, both hydroxyurea resistant and wild type cells were arrested in G1 phase with the phosphodiesterase inhibitor RO-1724. These data suggest that hydroxyurea resistant cells have increased ribonucleotide reductase activity due to increased M2 activity, possibly secondary to amplified genes(s) and exhibit abnormalities in cyclic AMP response.

3 PURINE DE NOVO SYNTHESIS AND SALVAGE DURING
TESTICULAR DEVELOPMENT IN THE RAT
Jennifer Allsop and Richard W.E. Watts
Division of Inherited Metabolic Diseases,
MRC Clinical Research Centre, Harrow HA1 3UJ, U.K.

Purine de novo synthesis and salvage occur in the testis. Cell division accelerates at puberty. We have correlated changes in the activity of purine de novo synthesis and purine salvage with the histology of the developing testis and with serum hormone levels. Purine de novo synthesis peaked at 17 days and HPRT activity at 35 days. APRT activity decreased at 17 days and remained very low. The 17 day peak of purine de novo synthesis coincided exactly with the appearance of spermatids and prominent spermatocytic meiosis. The 35 day HPRT peak coincided with the first appearance of active spermatogenesis, full thickness of precursor cells and fully fledged spermatozoa. These findings indicate that the full development of reproductive function in the male requires HPRT as well as purine de novo synthesis.

4 ALLOSTERIC CONTROL OF CTP SYNTHETASE IN VIVO.

Bruce Aronow and Buddy Ullman. Univ. of KY
Medical Center, Dept. of Biochemistry, Lexington,
KY, U.S.A. It has long been appreciated that CTP synthetase is an allosteric enzyme that is inhibited by its endproduct, CTP. The isolation and characterization of mutant murine T lymphoblasts with a genetically altered CTP synthetase activity which is refractory to inhibition by CTP have allowed an *in situ* determination of the essential regulatory factors governing pyrimidine synthesis and pyrimidine pool balance in a mammalian cell line. Metabolic flux and nucleotide pool measurements in unperturbed cycling cells and in cells in which the cellular pools have been exogenously manipulated indicated that the regulation of flux through CTP synthetase *in situ* occurs mainly by allosteric inhibition by CTP. Metabolic flux through CTP synthetase was arrested by imperceptible perturbations in CTP pools in wildtype cells but not in the mutant cells. Small changes in the levels of either ATP or GTP, a substrate and activator of the enzyme, respectively, had little influence on the *in situ* activity of CTP synthetase. The rates of pyrimidine synthesis are regulated in a similar fashion by uridylylate nucleotides in wildtype but not in mutant cells. Thus, uridylylate nucleotides govern the rates of *de novo* pyrimidine synthesis, while CTP modulates the balance between uridylylate and cytidylylate nucleotides.

5 ROLE OF THE NUCLEOSIDE TRANSPORT FUNCTION IN THE
TRANSPORT, INCORPORATION, AND SALVAGE OF
HYPOXANTHINE. Bruce Aronow and Buddy Ullman. Univ.

KY Medical Center, Dept. of Biochemistry, Lexington, KY, U.S.A. Genetic deficiencies in the nucleoside transport function markedly altered the abilities of cultured mutant S49 T lymphoblasts to transport, incorporate, and salvage exogenous hypoxanthine. The concentrations of hypoxanthine required to reverse azaserine toxicity and replenish azaserine-depleted nucleoside triphosphate pools in AE1 cells, a nucleoside transport-deficient clone, were about 10-fold higher than those required for wildtype cells. Surprisingly, a second nucleoside transport-deficient clone, 80-5D2, which had lost 80-90% of its ability to transport nucleosides, required lower hypoxanthine concentrations to reverse these azaserine-mediated effects. The addition of 10µM p-nitrobenzylthioinosine (NBMPR), a potent inhibitor of nucleoside transport, to wildtype cells mimicked the phenotype of the AE1 cells with respect to the hypoxanthine reversal of the effects of azaserine. AE1 cells or NBMPR-treated wildtype cells could only transport hypoxanthine at 20% the rate of untreated wildtype cells. The 80-5D2 cell line could transport and utilize hypoxanthine more efficiently than the wildtype parental cell line. A genetic deficiency in nucleoside transport did not interfere with adenine transport, incorporation, or salvage, however. These studies on S49 T lymphoblasts altered in their nucleoside transport capacity provide powerful genetic evidence that hypoxanthine and nucleosides share a common transport function.

6 ALTERATION OF RIBONUCLEOTIDE AND DEOXYRIBONUCLEOTIDE
METABOLISM BY INTERFERON IN HUMAN B-LYMPHOBLASTOID
CELLS. Jerzy Barankiewicz, Chaim Kaplinsky and
Amos Cohen. Division of Immunology, Research Institute, The
Hospital for Sick Children, Toronto, Ontario, Canada.

The effect of interferon on nucleic acid synthesis and on nucleotide metabolism was studied in human B-lymphoblastoid cells. Cells were incubated with 50 units/ml of recombinant α-interferon for 24 hrs. Synthesis of nucleic acids, ribonucleotides, deoxyribonucleotides as well as nucleotide interconversion and catabolism were determined. Interferon inhibited both DNA and RNA synthesis measured by the incorporation of radioactive thymidine and uridine respectively. Ribonucleotide and deoxyribonucleotide biosynthesis by both the *de novo* and salvage pathways was markedly inhibited by interferon whereas nucleotide catabolism was significantly increased. Interferon also decreased intracellular PRPP levels but had no effect on ribonucleotide interconversion or protein synthesis measured by incorporation of radioactive threonine, leucine and valine. These results showed that inhibition of nucleic acid synthesis by interferon is associated with decreased availability of nucleotides for synthesis of both DNA and RNA.